News Releases

Summary Toggle Teligent, Inc. Announces FDA Approval of Clobetasol Propionate Cream USP, 0.05%

BUENA, N.J. , April 17, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

April 17, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Ciclopirox Shampoo, 1%

BUENA, N.J. , April 06, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

April 6, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Halobetasol Propionate Ointment, 0.05%

BUENA, N.J. , March 21, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

March 21, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces Fourth Quarter and Year End 2017 Results

BUENA, N.J. , March 15, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2017 . Fourth Quarter 2017 Highlights Total revenues of $16.1 million

March 15, 2018

PDF Version
Summary Toggle Teligent, Inc. to Present at the Oppenheimer 28th Annual Healthcare Conference on Tuesday March 20, 2018

BUENA, N.J. , March 13, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Oppenheimer 28 th Annual Healthcare Conference. The Conference is taking place March 20-21, 2018 at the Westin Grand Central , New

March 13, 2018

PDF Version
Summary Toggle Teligent, Inc. to Hold Conference Call for Fourth Quarter 2017 Results

BUENA, N.J. , March 12, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Thursday March 15, 2018 to discuss the 4 th quarter 2017 financial results and business

March 12, 2018

PDF Version
Summary Toggle Teligent, Inc. to Present at the Raymond James 39th Annual Institutional Investors Conference on Wednesday March 7, 2018

BUENA, N.J. , March 05, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Raymond James 39th Annual Institutional Investors Conference . The Conference is taking place March 4-7, 2018 at the J.W.

March 5, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Betamethasone Dipropionate Lotion USP (Augmented), 0.05%

BUENA, N.J. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

February 14, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces the Appointment of Damian Finio as Chief Financial Officer

BUENA, N.J. , Jan. 26, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, announced today that Damian Finio has been appointed Chief Financial Officer of Teligent, Inc. , effective February 5, 2018 . Mr.

January 26, 2018

PDF Version
Summary Toggle Teligent, Inc. to Present at the J.P. Morgan 36th Annual Healthcare Conference January 10th

BUENA, N.J. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the J.P. Morgan 36 th Annual Healthcare Conference. The Conference is taking place January 8-11, 2018 at the Westin St.

January 3, 2018

PDF Version